

## Appendix 1. A detailed overview of the in- and exclusion criteria

**Table 1** Detailed in- and exclusion criteria

### General criteria

During the first screening for a potential study participant, the following individuals are deemed to be eligible candidates if they meet all of the following criteria:

- patient of any sex and gender aged at least 18 years at the time of study inclusion
- patient is potentially willing and able to understand and sign an informed consent form in German
- patient could declare their general willingness to participate in the study procedures, including to be contacted again for further follow-up examinations
- the patient's general health status is acceptable for a screening visit and potentially the subsequent participation in the study
- the patients meets one of the specific disease criteria (see below)

Eligible candidates are further screened during a visit. An individual who meets any of the following criteria during this visit will be subsequently excluded from study participation

- Incapable to give informed consent
- Pregnancy or lactation
- Life expectancy < 6 months due to non-cardio-/cerebrovascular diseases or conditions
- Organ transplanted
- Lack of health insurance
- Patients with active malignant cancer disease, that are currently in medical treatment OR for whom there is a medical indication for treatment OR who have been treated for the disease less than 6 months ago OR those experience complications of the disease including side effects of treatment.

### Specific disease criteria - Acute Heart Failure

Patient hospitalized for acute heart failure. This is defined as and in accordance with ESC guidelines [1]. More specifically:

- a documented diagnosis of acute heart failure ( $\geq$  NYHA II) OR clinical deterioration of preknown chronic heart failure
- AND documented escalation of preexisting loop diuretic therapy OR new prescription of loop diuretic therapy

### Specific disease criteria - Acute Coronary Syndrome

Patients hospitalized for Acute coronary syndrome type 1, 2 or 3, according to the "Fourth universal definition of MI 2018". [2]. More specifically:

- At least one of the following criteria either during a hospital stay or at the emergency service or at the emergency department:
  - characteristic of cardiac chest pain
  - anginal equivalents
- AND, at least one out of the following criteria:
  - Electrocardiographic manifestations, defined as
    - ST-segment elevation in two contiguous leads with the cut-points:  $\geq$  2.5mm in men < 40 years;  $\geq$  2mm in men  $\geq$ 40 years or  $\geq$  1.5mm in women regardless of age in the leads V2/V3
    - ST-segment elevation  $\geq$  1mm in the other leads
    - new-onset of LBBB/RBBB
    - ST-segment changes in the presence of a known BBB
    - ST-segment depression in  $\geq$  8 leads in the presence of ST-segment elevation in aVR/V1

- 
- the presence of pathological Q-waves.
  - Horizontal ST-segment depression of  $\geq 0.5\text{mm}$
  - T-wave inversions of  $\geq 1\text{mm}$  in at least 2 contiguous leads
  - Evidence of myocardial necrosis, defined as
    - Detection of elevation of hs-TnI or hs-TnT greater than the 99<sup>th</sup> percentile of URL
    - Normal hs-Tn baseline values at (hospital) admission with a dynamic change in hs-Tn values within 1 hour, confirmed through a hsTn specific assay.
- 

#### Specific disease criteria - Stroke

---

Patients hospitalized for cerebrovascular disease, defined as and in accordance with the ASA guidelines [3]. More specifically:

- A transient ischemic attack (TIA) with clinical restitution within 24 hours AND initial neurological deficit verified by a neurologist (that is a neurologist has personally detected and documented a clinical deficit on physical neurologic examination and assessed this deficit as compatible with a vascular syndrome/TIA) OR ABCD2-Score  $\geq 3$  OR visible lesion in cerebral imaging (e.g. DWI-lesion (MRI)) OR the main hospital diagnosis of is Amaurosis fugax
  - OR acute ischemic stroke including retinal central artery occlusion
  - OR stroke caused by non-traumatic intracerebral hemorrhage
  - OR stroke caused by cerebral venous thrombosis
- 

#### Specific disease criteria - Acute Kidney Injury

---

Patients who experience persisting (i.e.  $\geq 72$  hours ) Acute Kidney Injury stage 2 or stage 3 during their hospital stay, diagnosed and in accordance with KDIGO criteria [4]. KDIGO criteria:

- AKI stage 2 (KDIGO): serum creatinine 2.0-2.9 times baseline, urine output  $< 0.5\text{ ml/kg/h}$  for  $\geq 12$  hours
  - AKI stage 3 (KDIGO): serum creatinine  $\geq 3.0$  times baseline OR increase of serum creatinine to  $\geq 4.0\text{ mg/dl}$  ( $\geq 353,6\text{ }\mu\text{mol/l}$ ) OR initiation of renal replacement therapy, urine output: anuria for  $\geq 12$  hours
- 

#### Specific disease criteria - Diabetes Mellitus

---

Patients who are diagnosed with diabetes with target-organ damage, diagnosed and in accordance with various guidelines. More specifically

- Known diabetes mellitus type 2 characterized by pathological findings in oral glucose tolerance test OR documented HbA1c  $\geq 6.5\%$  OR Intake of any antidiabetic medication OR fasting blood glucose  $\geq 126\text{ mg/dl}$
  - AND signs of micro- or macrovascular damage defined as at least one of the following
    - Nephropathy: micro-/macroalbuminuria ( $>20\text{mg albumine/l}$  OR  $> 30\text{mg albumine/day}$  OR  $> 30\text{mg/g albumin/creatinine}$ ) OR decreased eGFR ( $< 60\text{ml/min}$ ) (American Diabetes Association, 2018; Nationale Versorgungsleitlinie diabetische Nierenerkrankungen, 2015)
    - Retinopathy: documented fundoscopic lesions (e.g. microaneurysms, intraretinal hemorrhage, diabetic maculopathy), previous laser therapy, previous injection therapy, previous vitrectomy, previous intervention because of neovascular glaucoma.[5]
    - Neuropathy: ( $\geq 2$ : decreased/ absent ankle jerk reflexes, decreased distal sensory perception (touch/pressure, vibration (dorsal hallux:  $< 30\text{yrs: } < 6/8$ ;  $> 30\text{yrs: } < 5/8$ ; medial malleolus:  $< 40\text{ yrs.: } < 6/8$ ;  $< 40\text{ yrs: } < 5/8$ ), pain, temperature), neuropathic symptoms (MNSI, NDS, NSS)[5,6]
    - Preexisting cardiovascular disease, being defined as coronary artery disease (previous ACS/ myocardial infarction, previous PTA, previous coronary bypass surgery, history of hybrid-intervention) or cerebrovascular disease (previous stroke, previous TIA), peripheral artery disease (ABI  $< 0,9$  or  $> 1,4$ , carotid plaque/atherosclerosis, mesenterial atherosclerosis or renal atherosclerosis in imaging, previous PTA, previous bypass surgery, previous hybrid-intervention, previous amputation, previous mesenteric ischemia).[7–9]
-

## references

1. Ponikowski P, Voors AA, Anker SD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure. *European journal of. Wiley Online Library*; 2016; Available: <https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.592>
2. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). *Circulation*. 2018;138: e618–e651.
3. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJB, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2013;44: 2064–2089.
4. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. *Kidney international supplements*. Nature Publishing Group; 2012;2: 1–138.
5. Ziemssen F, Lemmen K, Bertram B, Hammes HP, Agostini H. Nationale Versorgungsleitlinie (NVL) Diabetische Retinopathie [Internet]. *Der Ophthalmologe*. 2016. pp. 623–638. doi:10.1007/s00347-016-0315-8
6. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempner P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care*. 2010;33: 2285–2293.
7. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J*. 2018;39: 763–816.
8. Committee for Practice Guidelines ESC. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. academic.oup.com; 2013; Available: <https://academic.oup.com/eurheartj/article-abstract/34/38/2949/442952>
9. Catapano AL, Graham I, De Backer G. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and of the European Association of Cardiovascular Prevention and Rehabilitation. *Atherosclerosis*. atherosclerosis-journal.com; 2016; Available: [https://www.atherosclerosis-journal.com/article/S0021-9150\(16\)31267-9/abstract](https://www.atherosclerosis-journal.com/article/S0021-9150(16)31267-9/abstract)